|
|
Vaccine Comparison
|
NIpah Virus G and F Proteins Subunit Vaccine |
rMV-Ed-G |
| Vaccine Information |
Vaccine Information |
- Vaccine Ontology ID: VO_0011407
- Type: Subunit vaccine
- Status: Research
- F fusion protein
gene engineering:
- Type: Recombinant protein preparation
- Detailed Gene Information: Click Here.
- G glycoprotein
gene engineering:
- Type: Recombinant protein preparation
- Detailed Gene Information: Click Here.
- Immunization Route: Subcutaneous injection
|
- Vaccine Ontology ID: VO_0004714
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- G glycoprotein
gene engineering:
- Type: Recombinant vector construction
- Description: A recombinant measles virus (rMV) vaccine expressing NiV envelope glycoproteins (rMV-HL-G and rMV-Ed-G) (Yoneda et al., 2013).
- Detailed Gene Information: Click Here.
- Preparation: Recombinant measles virus (rMV) vaccine expressing NiV envelope glycoproteins (rMV-HL-G and rMV-Ed-G) (Yoneda et al., 2013).
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
Host Response |
|
Hamster Response
- Vaccination Protocol: For protection studies, inbred golden hamsters (Janvier, Le Fenest St. Isles, France) were vaccinated twice (1 month apart) with 107 PFU of vaccinia virus recombinants expressing either the G or F Nipah virus glycoprotein or with 5 × 106 of each of the recombinants when they were used for coimmunization (Guillaume et al., 2004).
- Challenge Protocol: The animals were challenged 3 months after the last immunization with Nipah virus administered interperitoneally (Guillaume et al., 2004).
- Efficacy: Hamsters immunized with F and G proteins were completely protected from lethal Nipah virus challenge (Guillaume et al., 2004).
|
Hamster Response
- Vaccination Protocol: 8-week-old golden hamsters were intraperitoneally immunized with 2×10^4 TCID50 of rMV-HL-G or rMV-Ed-G (Yoneda et al., 2013).
- Vaccine Immune Response Type: VO_0003057
- Challenge Protocol: All hamsters were challenged intraperitoneally with 10^3 TCID50/animal of NiV (Yoneda et al., 2013).
- Efficacy: All hamsters vaccinated with rMV-HL-G or rMV-Ed-G showed complete protection. During the observation period (14 days after the challenge), all hamsters immunized with the recombinant MVs showed no clinical symptoms of the disease and survived (Yoneda et al., 2013).
|
| References |
References |
Guillaume et al., 2004: Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefeuvre A, Marianneau P, Chua KB, Lam SK, Buckland R, Deubel V, Wild TF. Nipah virus: vaccination and passive protection studies in a hamster model. Journal of virology. 2004; 78(2); 834-840. [PubMed: 14694115].
|
Yoneda et al., 2013: Yoneda M, Georges-Courbot MC, Ikeda F, Ishii M, Nagata N, Jacquot F, Raoul H, Sato H, Kai C. Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge. PloS one. 2013; 8(3); e58414. [PubMed: 23516477].
|
|
